News
FBIO
2.170
-4.82%
-0.110
Corbus Pharmaceuticals Holdings Inc. Stock Sheds 4.2%, Underperforms Peers
Dow Jones · 3d ago
Weekly Report: what happened at FBIO last week (0914-0918)?
Weekly Report · 09/21 09:58
Corbus Pharmaceuticals Holdings Inc. Stock Rallies 4.9%, Outperforms Peers
Dow Jones · 09/16 20:34
Corbus Pharmaceuticals Holdings Inc. Stock Slides 14.4%, Underperforms Peers
Dow Jones · 09/15 20:33
Weekly Report: what happened at FBIO last week (0907-0911)?
Weekly Report · 09/14 10:02
Corbus Pharmaceuticals Holdings Inc. Stock Sheds 7.0%, Underperforms Peers
Dow Jones · 09/10 20:33
Corbus Pharmaceuticals Holdings Inc. Stock Slips 16.4%, Underperforms Peers
Dow Jones · 09/09 20:33
Weekly Report: what happened at FBIO last week (0831-0904)?
Weekly Report · 09/07 09:57
Weekly Report: what happened at FBIO last week (0824-0828)?
Weekly Report · 08/31 10:03
Corbus Pharmaceuticals Holdings Inc. Stock Rises 5.8%, Outperforms Peers
Dow Jones · 08/25 20:32
Fortress Biotech (FBIO) Receives a Buy from Alliance Global Partners
TipRanks · 08/24 16:15
Weekly Report: what happened at FBIO last week (0817-0821)?
Weekly Report · 08/24 10:03
Corbus Pharmaceuticals Holdings Inc. Stock Rallies 5.5%, Outperforms Peers
Dow Jones · 08/21 20:33
Corbus Pharmaceuticals Holdings Inc. Stock Rises 4.0%, Outperforms Peers
Dow Jones · 08/17 20:35
Weekly Report: what happened at FBIO last week (0810-0814)?
Weekly Report · 08/17 10:04
Press Release: Fortress Biotech Reports Second -2-
Dow Jones · 08/13 20:05
Press Release: Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Dow Jones · 08/13 20:05
Fortress Biotech: Q2 Earnings Snapshot
Barchart · 08/13 16:05
Press Release: Journey Medical Corporation -2-
Dow Jones · 08/12 20:01
Press Release: Journey Medical Corporation -3-
Dow Jones · 08/12 20:01
More
Webull provides a variety of real-time FBIO stock news. You can receive the latest news about Fortress Biotech Inc through multiple platforms. This information may help you make smarter investment decisions.
About FBIO
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.